MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Aquinox Pharmaceuticals Company Profile (NASDAQ:AQXP)

Consensus Ratings for Aquinox Pharmaceuticals (NASDAQ:AQXP) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $8.67 (49.35% downside)

Analysts' Ratings History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Show:
DateFirmActionRatingPrice TargetActions
8/10/2015Cowen and CompanyBoost Price TargetOutperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/10/2015Jefferies GroupDowngradeBuy -> Hold$13.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2015Cowen and CompanyReiterated RatingBuy$16.44View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/25/2015Canaccord GenuityReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/15/2015Canaccord GenuitySet Price TargetBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2015Canaccord GenuityBoost Price TargetBuy$12.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/16/2014Canaccord GenuityInitiated CoverageBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2014Jefferies GroupReiterated RatingBuy$17.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/16/2014Canaccord GenuityInitiated CoverageBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2014Cowen and CompanyInitiated CoverageOutperform$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2014Jefferies GroupInitiated CoverageBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/31/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha